Aimei Health (AFJK) shifts board as Huh exits and Polvi joins
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Aimei Health Technology Co., Ltd. reports a board change. On June 24, 2026, director Julianne Huh resigned for personal reasons, with no disagreement on the company’s operations, policies, or practices. She confirmed all compensation has been paid and released the company from any related claims.
On June 29, 2026, the board appointed Daniel Veikko Polvi as a new director. He holds an MBA from Norwegian Business School and has served since May 2019 as managing director of Shearwater Limited, providing business management and strategic consulting services to international corporations. The company states there are no family relationships or related-party transactions requiring disclosure.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Resignation effective date: June 24, 2026
Appointment date: June 29, 2026
Ordinary share par value: $0.0001 per share
+3 more
6 metrics
Resignation effective date
June 24, 2026
Effective date of director Julianne Huh’s resignation
Appointment date
June 29, 2026
Date Daniel Veikko Polvi was approved and appointed as director
Ordinary share par value
$0.0001 per share
Par value of Aimei Health Technology’s ordinary shares listed on Nasdaq
Ordinary Share trading symbol
AFJK
Ticker for ordinary shares on The Nasdaq Stock Market LLC
Rights trading symbol
AFJKR
Ticker for rights exchangeable into one-fifth of one ordinary share
Units trading symbol
AFJKU
Ticker for units consisting of one ordinary share and one right
Key Terms
Emerging growth company, Item 5.02, nominating and corporate governance committee, Item 404(a) of Regulation S-K, +1 more
5 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02. Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 5.02 regulatory
"Item 5.02. Departure of Directors or Certain Officers; Election of Directors"
nominating and corporate governance committee financial
"On June 29, 2026, the nominating and corporate governance committee of the Board recommended"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Item 404(a) of Regulation S-K regulatory
"not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"
FAQ
What board change did Aimei Health Technology (AFJK) disclose?
Aimei Health Technology disclosed that director Julianne Huh resigned effective June 24, 2026, for personal reasons. The board subsequently appointed Daniel Veikko Polvi as a new director on June 29, 2026, to fill the vacancy created by her resignation.
Why did Julianne Huh resign from Aimei Health Technology (AFJK)?
Julianne Huh resigned as a director of Aimei Health Technology on June 24, 2026, citing personal reasons. The company states her resignation did not result from any disagreement regarding its operations, policies, or practices, indicating this is a non-dispute-related governance change.
Did Aimei Health Technology (AFJK) owe any payments to Julianne Huh after her resignation?
Aimei Health Technology states Julianne Huh acknowledged she has been paid all amounts due to her. She is not entitled to any further payments or benefits and has irrevocably released the company from all related claims and causes of action.
Who is the new director appointed to Aimei Health Technology (AFJK)?
The board appointed Daniel Veikko Polvi as a director on June 29, 2026. He holds an MBA from Norwegian Business School and serves as managing director of Shearwater Limited, a management consulting firm for international corporate clients.
Is Aimei Health Technology (AFJK) classified as an emerging growth company?
Yes. The filing indicates Aimei Health Technology qualifies as an emerging growth company under Rule 12b-2 of the Securities Exchange Act. This status can allow scaled disclosure and certain regulatory accommodations for relatively newly public or smaller issuers.